NEW YORK, NY--(Marketwired - September 02, 2015) - Daxor Corporation, (NYSE MKT: DXR), a medical instrumentation and biotechnology company, announced today the appointment of Lisa Quartley as its first SVP, Marketing and Commercial Development. Ms. Quartley will be leading a newly focused and reinvigorated commercialization effort for the company's unique diagnostic technology with the goal of making direct blood volume measurement a standard of care.
A seasoned marketing strategist with over fifteen years of US and global experience in complex, high-science specialty healthcare settings, Ms. Quartley has proven her ability to trigger and accelerate the disruptive landscape realignments that move advances in care from lab to podium to patient. Her track record of successful asset optimization extends across a variety of maturity, midcycle, launch, and prelaunch scenarios. Within the past five years she has led consultancy-side strategic efforts for key brands at Genentech, Novartis, Bristol-Myers Squibb, and Eisai. Her expertise includes branding and positioning, sales strategy and training, scientific engagement, experience planning and channel strategy, pipeline, label crafting, portfolio/franchise, life cycle, and competitive planning. Ms. Quartley received her M.A. from Harvard University and her B.A. from Yale University.
"I am excited to help connect the medical community with an important technology that I believe serves an underrecognized and very significant unmet medical need," said Ms. Quartley. "I look forward to working with the Daxor team to make a meaningful difference to the numerous and diverse patients who stand to benefit from this advance in diagnostic technology, building upon the great work that has been done to date to develop it."
Blood volume derangement is a core driver of pathology across a diverse range of major medical problems, including congestive heart failure, sepsis in intensive care, and kidney failure, where blood volume measurement has the potential to help rationalize and optimize clinical assessment and treatment calibration. To date, direct blood volume measurement is significantly underutilized. The BVA-100 Blood Volume Analyzer is currently in use at 67 hospitals in the U.S., including NYU Medical Center, the Cleveland Clinic, and the Mayo Clinic. Daxor's website provides important additional information to help physicians and patients understand the benefit of blood volume measurement, as well as the names of medical facilities currently able to provide this life-saving diagnostic test.
"This technology should be in every hospital in the country," noted Michael Feldschuh, Executive Vice-President at Daxor. "Lisa has the experience we need in disseminating understanding, building awareness, and generating excitement to advance the standard of care. I am confident that bringing her on board will power Daxor to a new level of success in realizing the benefits of this important innovation for clinicians and patients."
To learn more about Daxor, please visit www.Daxor.com.
(SVP, Marketing and Commercial Development)
(Executive Vice President)